title: Discovery of lucensimycins A and B from Streptomyces lucensis MA7349 using an antisense strategy.
abstract: Inhibition of protein synthesis is one of the validated and highly successful targets for inhibition of bacterial growth; this mechanism is a target of a large number of clinical drugs. Ribosomal protein S4, a primary protein, is a potential target for the discovery of antibacterial agents. We describe, using an antisense-sensitized rpsD Streptomyces aureus strain, the discovery and activity of lucensimycins A and B. [structure: see text].
authors.affiliation: Merck Research Laboratories, Rahway, New Jersey 07065, USA. sheo_singh@merck.com
authors.forename: Sheo B
authors.initials: SB
authors.lastname: Singh
authors.forename: Deborah L
authors.initials: DL
authors.lastname: Zink
authors.forename: Joanne
authors.initials: J
authors.lastname: Huber
authors.forename: Olga
authors.initials: O
authors.lastname: Genilloud
authors.forename: Oscar
authors.initials: O
authors.lastname: Salazar
authors.forename: M Teresa
authors.initials: MT
authors.lastname: Diez
authors.forename: Angela
authors.initials: A
authors.lastname: Basilio
authors.forename: Francisca
authors.initials: F
authors.lastname: Vicente
authors.forename: Kevin M
authors.initials: KM
authors.lastname: Byrne
mesh_terms: D000900:Anti-Bacterial Agents / Q000096:biosynthesis* / Q000494:pharmacology; D016373:DNA, Antisense / Q000235:genetics*; D004269:DNA, Bacterial / Q000235:genetics; D015195:Drug Design; D009682:Magnetic Resonance Spectroscopy; D013058:Mass Spectrometry; D008826:Microbial Sensitivity Tests; D008958:Models, Molecular; D013141:Spiro Compounds / Q000494:pharmacology; D013302:Streptomyces / Q000235:genetics* / Q000378:metabolism*
chemical_list: D000900:Anti-Bacterial Agents; D016373:DNA, Antisense; D004269:DNA, Bacterial; D013141:Spiro Compounds; C522747:lucensimycin A; C522748:lucensimycin B